Exhibit 10.30


 


Certain
personally identifiable information contained in this document, marked by brackets as [***], has been omitted from this exhibit pursuant
to Item 601(a)(6) under Regulation S-K.


 


Amendment
to the Loan Agreement dated as of October 15, 2021, as amended


 


of
February 15, 2022


 


between


 


	1.	Biotechnology
                                            Value Fund, L.P.



44
Montgomery Street, 40th Floor


San
Francisco, CA 94104, USA


[***]


(hereinafter
“Lender 1”)


 


	2.	Biotechnology
                                            Value Fund II, L.P.



44
Montgomery Street, 40th Floor


San
Francisco, CA 94104, USA


[***]


(hereinafter
“Lender 2”)


 


	3.	Biotechnology
                                            Value Trading Fund OS, L.P.



PO
Box 309 Ugland House, Grand Cayman


KY1-1104,
Cayman Islands


[***]


(hereinafter
“Lender 3”)


 


(each
a “Lender” and collectively the “Lenders”)


 


and


 


		4.	MoonLake
                                            Immunotherapeutics AG



Dorfstrasse
29


6300
Zug, Switzerland


		[***]	



(hereinafter
the “Borrower”)


 


(the
Lenders, the Borrower each a “Party” and collectively the “Parties”)


 




     


     


    

 	Amendment to
the Loan Agreement dated as of October 15, 2021, as amended




 


TAble
of contents


 


	Preamble


	3
	 	 	 
	1.	Definitions	3
	 	 	 
	2.	Amendment Section 6 (Term and
    Repayment) of the Loan Agreement	3
	 	 	 
	3.	Continuity	4
	 	 	 
	4.	Term of this Amendment Agreement	4
	 	 	 
	5.	Miscellaneous	4
	 	 	 
	6.	Applicable law and jurisdiction	4


  




    2


    


    

 


	Amendment to
the Loan Agreement dated as of October 15, 2021, as amended



 


	Preamble	



 


	A.	On
                                            October 15, 2021, the Parties entered into a Loan Agreement regarding certain loans in the
                                            total amount of USD 15,000,000 (the “Loan Agreement”).



 


	B.	The
                                            Loans (as defined in the Loan Agreement) granted under the Loan Agreement were granted for
                                            a fixed period of time until the Maturity Date (as defined in the Loan Agreement).



 


	C.	On
                                            January 18, 2022, the Parties amended the loan to extend the Maturity Date to the earlier
                                            of (i) the Transaction Closing (as defined in the Loan Agreement) and (ii) March 31, 2022,
                                            under the terms and conditions set out in this agreement.



 


	D.	The
                                            Parties now intend to further extend the Maturity Date to the earlier of (i) the Transaction
                                            Closing (as defined in the Loan Agreement) and (ii) June 30, 2022, under the terms and conditions
                                            set out in this agreement (the “Amendment Agreement”)



 


Now,
therefore, the Parties agree as follows:


 


	1.	Definitions



 


Capitalized
terms used in this Amendment Agreement shall have the respective meanings as set forth in the Loan Agreement.


 


	2.	Amendment
                                            Section 6 (Term and Repayment) of the Loan Agreement



 


The
Parties agree to replace Section 6 of the Loan Agreement in its entirety with the following section:


 


		6.	TERM
AND REPAYMENT



 


The
Loans granted hereunder are granted for a fixed period of time until the earlier of (i) as soon as practicable after the Transaction
Closing, but no later than two (2) business days, and (ii) June 30, 2022 (the “Maturity Date”).


 


The
Loans may be repaid in whole or in part by the Borrower at any time on or prior to the Maturity Date. 


 






    3


    


    

 


	3.	Continuity



 


The
existing provisions of the Loan Agreement shall, except as amended in this Amendment Agreement, continue in full force and effect,
and shall be read and construed as one document together with this Amendment Agreement.


 


	4.	Term
                                            of this Amendment Agreement



 


This
Amendment Agreement shall enter into force upon signature by all Parties and shall automatically end upon termination of the Loan Agreement.


 


	5.	Miscellaneous



 


Section
12 of the Loan Agreement shall apply to this Amendment Agreement.


 


	6.	Applicable
                                            law and jurisdiction



 


This
Amendment Agreement shall in all respects be governed by and construed in accordance with Swiss law under the exclusion of its private
international law provisions and international treaties.


 


Any
dispute, controversy or claim arising out of, or in relation to, this con-tract, including the validity, invalidity, breach, or termination
thereof, shall be subject to the exclusive jurisdiction of the courts of Zug, Canton of Zug, Switzerland.


 


[signature
page to follow]


 




    4


    


    

 


	Amendment to
the Loan Agreement dated as of October 15, 2021, as amended



 


	Lender 1	 	 
	 	 	 
	Signature:  	/s/
Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	Chief Executive Officer BVF I GP LLC, itself

 General Partner of Biotechnology Value Fund, L.P.
	 	 	 
	Lender 2	 	 
	 	 	 
	Signature:	/s/
Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	Chief Executive Officer BVF II GP LLC, itself 

General Partner of Biotechnology Value Fund II, L.P.
	 	 	 
	Lender 3	 	 
	 	 	 
	Signature:	/s/
Mark Lampert	 
	Name:	Mark Lampert	 
	Title:	President BVF Inc., General Partner of BVF Partners L.P.,

 itself sole member of BVF Partners OS Ltd., 

itself GP of Biotechnology Value Trading Fund OS, L.P.


 


Borrower


 


MoonLake
Immunotherapeutics AG


 


	Signature:  	/s/ Jorge Santos
    da Silva	 
	Name:	Jorge Santos da Silva	 
	Title:	CEO	 
	 	 	 
	Signature:	/s/ Matthias Bodenstedt	 
	Name:	Matthias Bodenstedt	 
	Title:	CFO	 



 


 


5